were in the adjuvant setting and 55.8% in palliative cases. The chemotherapy protocol depended on the histological type and was dominated by the 5FU-oxaliplatin combination in carcinomas, while the stromal tumors received TKI. After a median followup of 52.7 months, the median progression-free survival was 11.2 months and the median overall survival was 16.8 months all histological types combined.
Conclusion:Malignant tumors of the small intestine pose diagnostic problems because of their scarcity and the absence of specific clinical signs. They are often operative discoveries in the event of an acute complication. The curative treatment is surgical resection regardless of the histological type. The prognosis remains reserved because of the late diagnosis of the tumor.Legal entity responsible for the study: The author.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.